Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZYMOX is a brand name associated with two distinct therapeutic categories: a veterinary enzymatic system for topical infections and a human oral antibiotic. The veterinary line, developed by PKB Animal Health, features the patented LP3 Enzyme System, which consists of three essential enzymes—lactoperoxidase, glucose oxidase, and lysozyme—often supplemented with lactoferrin. This system exerts a broad-spectrum antimicrobial effect by disrupting microbial cell walls and metabolic pathways, making it effective against bacterial, fungal, and yeast infections (including MRSA and *Pseudomonas*) in companion animals. Some veterinary formulations also include hydrocortisone to manage inflammation and pruritus. Separately, in certain international markets, Zymox is used as a trade name for amoxicillin, a beta-lactam antibiotic manufactured by companies such as Alkem Laboratories and Smilax Pharmaceuticals, indicated for human respiratory, urinary, and systemic bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZYMOX.